Chiara Zecca1,2, Adam Czaplinski3, Christophe Henny4, Liliane Petrini1, Andreas Beeler5, Claudio Gobbi1,2. 1. Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland. 2. Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. 3. Neurozentrum Bellevue, Theaterstrasse 8, 8001 Zurich, Switzerland. 4. Clinique de La Source, Avenue Bergières 2, 1004 Lausanne, Switzerland. 5. Biogen Switzerland AG, Neuhofstrasse 30, 6340 Baar, Switzerland.
Abstract
BACKGROUND: Delayed-released dimethyl fumarate (DMF) is an oral disease-modifying therapy (DMT) approved for treating patients with multiple sclerosis (MS). This post-marketing study aimed at collecting real-world data on the safety, effectiveness, and tolerability of DMF in patients with relapsing remitting multiple sclerosis (RRMS). METHODS: 1-year post-marketing survey of patients prescribed DMF followed-up quarterly in hospital setting and private neurological practices in Switzerland from January 2015 to January 2018. Data on relapses, Expanded disability status scale (EDSS) score change, safety, tolerability, treatment adherence as judged by the treating neurologist and satisfaction were collected. Patients could refer to a patient support program. RESULTS: Of the 158 patients, 67 (42.4%) were treatment naïve, 91 (57.6%) switched from a prior MS DMT to DMF, 131 (82.9%) were treatment adherent, 108 (68.4%) used the support program, and 45 (28.5%) discontinued the therapy. Insufficient tolerability and insufficient effectiveness were the main reasons for discontinuation. 134 (84.8%) patients remained relapse free, 97 (61.4%) had stable or decreased EDSS score after 12 months. 74 (46.8%) patients reported adverse events; of these, 28 (17.7%) discontinued DMF treatment. Physicians and patients rated treatment satisfaction similarly (median score 8.0 of 10). CONCLUSIONS: The results obtained from this real-world observation are consistent with the efficacy and safety findings reported in pivotal and larger observational trials evaluating DMF treatment. Most side effects were experienced early after therapy initiation reflecting the timing of therapy discontinuation.
BACKGROUND: Delayed-released dimethyl fumarate (DMF) is an oral disease-modifying therapy (DMT) approved for treating patients with multiple sclerosis (MS). This post-marketing study aimed at collecting real-world data on the safety, effectiveness, and tolerability of DMF in patients with relapsing remitting multiple sclerosis (RRMS). METHODS: 1-year post-marketing survey of patients prescribed DMF followed-up quarterly in hospital setting and private neurological practices in Switzerland from January 2015 to January 2018. Data on relapses, Expanded disability status scale (EDSS) score change, safety, tolerability, treatment adherence as judged by the treating neurologist and satisfaction were collected. Patients could refer to a patient support program. RESULTS: Of the 158 patients, 67 (42.4%) were treatment naïve, 91 (57.6%) switched from a prior MS DMT to DMF, 131 (82.9%) were treatment adherent, 108 (68.4%) used the support program, and 45 (28.5%) discontinued the therapy. Insufficient tolerability and insufficient effectiveness were the main reasons for discontinuation. 134 (84.8%) patients remained relapse free, 97 (61.4%) had stable or decreased EDSS score after 12 months. 74 (46.8%) patients reported adverse events; of these, 28 (17.7%) discontinued DMF treatment. Physicians and patients rated treatment satisfaction similarly (median score 8.0 of 10). CONCLUSIONS: The results obtained from this real-world observation are consistent with the efficacy and safety findings reported in pivotal and larger observational trials evaluating DMF treatment. Most side effects were experienced early after therapy initiation reflecting the timing of therapy discontinuation.
Authors: Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen Journal: Lancet Neurol Date: 2017-12-21 Impact factor: 44.182
Authors: Giulia Mallucci; P Annovazzi; S Miante; V Torri-Clerici; M Matta; S La Gioia; R Cavarretta; V Mantero; G Costantini; V D'Ambrosio; M Zaffaroni; A Ghezzi; P Perini; S Rossi; A Bertolotto; M R Rottoli; M Rovaris; R Balgera; P Cavalla; C Montomoli; R Bergamaschi Journal: J Neurol Date: 2018-06-14 Impact factor: 4.849
Authors: Alexander Rae-Grant; Gregory S Day; Ruth Ann Marrie; Alejandro Rabinstein; Bruce A C Cree; Gary S Gronseth; Michael Haboubi; June Halper; Jonathan P Hosey; David E Jones; Robert Lisak; Daniel Pelletier; Sonja Potrebic; Cynthia Sitcov; Rick Sommers; Julie Stachowiak; Thomas S D Getchius; Shannon A Merillat; Tamara Pringsheim Journal: Neurology Date: 2018-04-24 Impact factor: 9.910
Authors: Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Carrie M Hersh; Thomas E Love; Samuel Cohn; Claire Hara-Cleaver; Robert A Bermel; Robert J Fox; Jeffrey A Cohen; Daniel Ontaneda Journal: Mult Scler Relat Disord Date: 2016-08-08 Impact factor: 4.339